Veroscience patents expiration
1. Cycloset patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866584 | VEROSCIENCE | Therapeutic process for the treatment of the pathologies of type II diabetes |
Nov, 2012
(11 years ago) | |
| US5756513 | VEROSCIENCE | Therapeutic process for the treatment of the pathologies of type II diabetes |
Nov, 2012
(11 years ago) | |
| US5468755 | VEROSCIENCE | Therapeutic process for the treatment of the pathologies of Type II diabetes |
Nov, 2012
(11 years ago) | |
| US5679685 | VEROSCIENCE | Accelerated release composition containing bromocriptine |
Oct, 2014
(9 years ago) | |
| US5716957 | VEROSCIENCE | Method for modifying and resetting the bloodstream prolactin levels of a human subject |
Feb, 2015
(9 years ago) | |
| US8137992 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(8 months ago) | |
| US8137993 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(8 months ago) | |
| US7888310 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy |
Jul, 2023
(8 months ago) | |
| US8137994 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(8 months ago) | |
| US9352025 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US10688155 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US9895422 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US8877708 | VEROSCIENCE | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US8613947 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US8431155 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9700555 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US10688094 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9993474 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9522117 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US11000522 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9192576 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2012 |
Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient
Market Authorisation Date: 05 May, 2009
Treatment: Improvement of glycemic control in individuals with type 2 diabetes; Improvements of glycemic control in individuals with type 2 diabetes who have one or more specified cardiovascular risk factors; Ad...
Dosage: TABLET;ORAL
More Information on Dosage
CYCLOSET family patents
